Revolution Medicines Stock Forecast

Stock Price Forecast

According to 22 analysts polled by S&P Global, Revolution Medicines stock has a consensus rating of "Strong Buy" and an average price target of $186.33. The average 1-year stock price forecast is 24.86% higher than the current stock price, while the lowest is $151 (+1.19%) and the highest is $263 (+76.24%).

Price Target: $186.33 (+24.86%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$151	$186.33	$183	$263
Change	+1.19%	+24.86%	+22.63%	+76.24%

Analyst Ratings

The average analyst rating for Revolution Medicines stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	16	17	17	17	17	17
Buy	4	4	4	4	4	4
Hold	0	0	0	0	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	20	21	21	21	22	22

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Alec Stranahan Bank of America Securities	Bank of America Securities	Buy Maintains $185	Buy	Maintains	$185	+23.97%	Jun 3, 2026
Unknown Analyst Bernstein No rating	Bernstein	Hold Maintains n/a	Hold	Maintains	n/a	n/a	Jun 2, 2026
Brian Cheng J.P. Morgan	J.P. Morgan	Buy Maintains n/a	Buy	Maintains	n/a	n/a	Jun 2, 2026
Robert Burns H.C. Wainwright	H.C. Wainwright	Buy Reiterates $169 → $195	Buy	Reiterates	$169 → $195	+30.67%	Jun 1, 2026
Marc Frahm TD Cowen	TD Cowen	Buy Maintains n/a	Buy	Maintains	n/a	n/a	Jun 1, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

99.96M

Revenue Next Year

845.43M

from 99.96M

745.76%

from 99.96M

EPS This Year

-8.02

from -5.95

EPS Next Year

-5.64

from -8.02

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	29.39M	35.38M	11.58M	-	-	99.96M
Gross Profit	-157.56M	-217.69M	-407.86M	-592.23M	-987.33M	94.26M
Gross Margin	-536.09%	-615.30%	-3,522.14%	-	-	94.30%
Operating Income	-188.01M	-258.28M	-475.99M	-689.52M	-1.18B	-1.70B
Net Income	-187.09M	-248.71M	-436.37M	-600.09M	-1.13B	-1.65B
EPS	-	-	-	-	-5.95	-8.02
Free Cash Flow	-84.69M	-132.84M	-163.95M	-347.69M	-523.28M	-1.38B
No. Analysts	-	-	-	-	-	20

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	295.1M
Avg	100.0M
Low	n/a

Revenue Growth

Revenue Growth	2027	2028
High	2,315.6%
Avg	745.8%
Low	43.5%

EPS Forecast

EPS	2026	2027	2028
High	-7.20
Avg	-8.02
Low	-8.81

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-